miR-98 is a key regulator of EZH2 and, according to the investigation of Liu et al., treatment of ovarian cancer stem cells with an expression plasmid containing EZH2-targeted miR-98 blocked cell growth, and ameliorated cell cycle status via increasing p21CIPI/WAF1 and E2F1 tumor suppressors and downregulating c-Myc and CDK2/cyclin E complex proto-oncogenes [126]. The gene discussed is EZH2; the disease is ovarian cancer.